Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
US6894024B2 · kind B2 · utility
61Cited by
4References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 22, 2001 |
| Grant date | May 17, 2005 |
| Priority date | — |
| Expiry date | Jan 24, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Hibernating myocardium is characterized by viable myocardium with impaired function due to localized reduced perfusion. Hibernating myocytes retain cellular integrity, but cannot sustain high-energy requirements of contraction. High plasma levels of catecholamines, such as norepinepherine, are believed to be predictive of mortality from hibernating myocardium. Likewise, high levels of catecholamines lead to cardiomyopathy in patients with diabetes. GLP-1 reduces plasma norepinepherine levels, and it thus is useful in a method of treating hibernating myocardium or diabetic cardiomyopathy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.